Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study

Main Article Content

Robert P. Baughman
Rohit Gupta
Marc Judson
Elyse Lower
Surinder Birrinder
Jeffrey Stewart
Rebecca Reeves
Athol Wells


pulmonary fibrosis, pirfenidone, advanced sarcoidosis, DLCO


Download data is not yet available.
Abstract 250 | PDF Downloads 124


1. Swigris JJ, Olson AL, Huie TJ et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011;183(11):1524-1530.
2. Nardi A, Brillet PY, Letoumelin P et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011;38(6):1368-1373.
3. Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest 2018;153(1):105-113.
4. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16(Sep):149-173.
5. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177(11):1248-1254.
6. Baughman RP, Shlobin OA, Wells AU et al. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 2018;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub;%2018 May 5.:72-78.
7. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159(1):179-187.
8. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948-968.
9. Walsh SL, Wells AU, Sverzellati N et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014;2(2):123-130.
10. Wells AU, Desai SR, Rubens MB et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167(7):962-969.
11. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007;132(1):207-213.
12. Patel AS, Siegert RJ, Creamer D et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013;68(1):57-65.
13. de Vries J, Michielsen H, van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004;9(Pt 3):279-291.
14. Patel AS, Siegert RJ, Keir GJ et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013;107(9):1438-1443.
15. Papiris SA, Daniil ZD, Malagari K et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005;99(6):755-761.
16. Jeny F, Uzunhan Y, Lacroix M et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med 2020;169:105997. doi: 10.1016/j.rmed.2020.105997. Epub@2020 May 12.:105997.

Most read articles by the same author(s)

1 2 3 > >>